Genomic analysis and filtration of novel prognostic biomarkers based on metabolic and immune subtypes in pancreatic cancer
Cellular Oncology · 2023
DOI: 10.1007/s13402-023-00836-3 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cellular Oncology, 2023. Verfasst von Guangyu Chen und 11 weiteren Autor:innen. Beteiligte Einrichtung: General Surgery Department, State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Chinese Academy of Medic…. Hauptthemen laut MEDLINE: Genomics, Pancreatic Neoplasms. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 62 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: China Postdoctoral Science Foundation, Youth Research Fund of Peking Union Medical College Hospital, National High Level Hospital Clinical Research Funding.
Abstract (Originalsprache)
PURPOSE: Patients with pancreatic cancer (PC) can be classified into various molecular subtypes and benefit from some precise therapy. Nevertheless, the interaction between metabolic and immune subtypes in the tumor microenvironment (TME) remains unknown. We hope to identify molecular subtypes related to metabolism and immunity in pancreatic cancer METHODS: Unsupervised consensus clustering and ssGSEA analysis were utilized to construct molecular subtypes related to metabolism and immunity. Diverse metabolic and immune subtypes were characterized by distinct prognoses and TME. Afterward, we filtrated the overlapped genes based on the differentially expressed genes (DEGs) between the metabolic and immune subtypes by lasso regression and Cox regression, and used them to build risk score signature which led to PC patients was categorized into high- and low-risk groups. Nomogram were built to predict the survival rates of each PC patient. RT-PCR, in vitro cell proliferation assay, PC organoid, immunohistochemistry staining were used to identify key oncogenes related to PC RESULTS: High-risk patients have a better response for various chemotherapeutic drugs in the Genomics of Drug Sensitivity in Cancer (GDSC) database. We built a nomogram with the risk group, age, and the number of positive lymph nodes to predict the survival rates of each PC patient with average 1-year, 2-year, and 3-year areas under the curve (AUCs) equal to 0.792, 0.752, and 0.751. FAM83A, KLF5, LIPH, MYEOV were up-regulated in the PC cell line and PC tissues. Knockdown of FAM83A, KLF5, LIPH, MYEOV could reduce the proliferation in the PC cell line and PC organoids CONCLUSION: The risk score signature based on the metabolism and immune molecular subtypes can accurately predict the prognosis and guide treatments of PC, meanwhile, the metabolism-immune biomarkers may provide novel target therapy for PC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- General Surgery Department, State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100730, China.
- Department of Breast Surgery, The Affiliated Hospital of Guizhou Medical University, Guizhou Medical University, Guiyang, China.
- Key Laboratory of Research in Pancreatic Tumor, Chinese Academy of Medical Sciences, Beijing, 100023, People's Republic of China.
- National Science and Technology Key Infrastructure on Translational Medicine in Peking Union Medical College Hospital, Beijing, 100023, People's Republic of China.
- Department of Liver Surgery, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
- General Surgery Department, State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100730, China.…
Förderung
- China Postdoctoral Science Foundation
- Youth Research Fund of Peking Union Medical College Hospital
- National High Level Hospital Clinical Research Funding
- National Natural Science Foundation of China
- Natural Science Foundation of Beijing
- CAMS Innovation Fund for Medical Sciences (CIFMS)
- National Key R&D Program of China
- Non-profit Central Research Institute Fund of Chinese Academy of Medical Sciences
Zitieren
APA
Chen, G., Liu, Y., Su, D., Qiu, J., Long, J., Zhao, F., Tao, J., Yang, G., Huang, H., Xiao, J., Zhang, T., & Zhao, Y. (2023). Genomic analysis and filtration of novel prognostic biomarkers based on metabolic and immune subtypes in pancreatic cancer. Cellular Oncology. https://doi.org/10.1007/s13402-023-00836-3
Vancouver
Chen G, Liu Y, Su D, Qiu J, Long J, Zhao F, et al. Genomic analysis and filtration of novel prognostic biomarkers based on metabolic and immune subtypes in pancreatic cancer. Cellular Oncology. 2023. doi:10.1007/s13402-023-00836-3
BibTeX
@article{Chen2023,
author = {Chen, Guangyu and Liu, Yueze and Su, Dan and Qiu, Jiangdong and Long, Junyu and Zhao, Fangyu and Tao, Jinxin and Yang, Gang and Huang, Hua and Xiao, Jianchun and Zhang, Taiping and Zhao, Yupei},
title = {Genomic analysis and filtration of novel prognostic biomarkers based on metabolic and immune subtypes in pancreatic cancer},
journal = {Cellular Oncology},
year = {2023},
doi = {10.1007/s13402-023-00836-3}
}
EUVIMED